CXCL12 links bladder cancer and diabetes as a potential biomarker
(2025) In Scientific Reports 15(1).- Abstract
Bladder cancer (BLCA) and diabetes mellitus (DM) are two prevalent diseases that may share molecular mechanisms, suggesting potential links between metabolic disorders and cancer. Using bioinformatics approaches, we integrated multiple databases to identify common genes between BLCA and DM, screening for potential biomarkers. CXCL12 (C-X-C motif chemokine 12, also known as stromal cell-derived factor 1, SDF-1) was ultimately identified as a key gene, followed by comprehensive analyses including immune infiltration analysis, functional enrichment analysis, survival analysis, clinicopathological correlation analysis, TIDE immune prediction scoring, and immunophenoscore (IPS) scoring comparison. The results indicate that CXCL12 is... (More)
Bladder cancer (BLCA) and diabetes mellitus (DM) are two prevalent diseases that may share molecular mechanisms, suggesting potential links between metabolic disorders and cancer. Using bioinformatics approaches, we integrated multiple databases to identify common genes between BLCA and DM, screening for potential biomarkers. CXCL12 (C-X-C motif chemokine 12, also known as stromal cell-derived factor 1, SDF-1) was ultimately identified as a key gene, followed by comprehensive analyses including immune infiltration analysis, functional enrichment analysis, survival analysis, clinicopathological correlation analysis, TIDE immune prediction scoring, and immunophenoscore (IPS) scoring comparison. The results indicate that CXCL12 is associated with altered immune cell function and tumor characteristics under elevated blood glucose levels, influencing the tumor microenvironment and promoting disease progression. The results elucidate the molecular underpinnings of BLCA and DM, establishing a basis for subsequent investigations into common mechanisms and the formulation of targeted therapeutic approaches. Research on shared biomarkers, such as CXCL12, between metabolic diseases and tumors aids in the precise prevention and control of comorbidities’ adverse effects on tumor progression. This approach significantly reduces the health burden linked to comorbidities.
(Less)
- author
- Ma, Mingyu ; Wang, Shufei ; Wang, Kongjia LU ; Jiang, Bo ; Li, Jingwen and Hou, Sichuan
- organization
- publishing date
- 2025-12
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Biomarker, Bladder cancer, CXCL12, Diabetes mellitus, Epithelial-mesenchymal transition (EMT), Tumor microenvironment (TME)
- in
- Scientific Reports
- volume
- 15
- issue
- 1
- article number
- 19017
- publisher
- Nature Publishing Group
- external identifiers
-
- scopus:105006905053
- pmid:40447619
- ISSN
- 2045-2322
- DOI
- 10.1038/s41598-025-01357-9
- language
- English
- LU publication?
- yes
- id
- 8610341d-ebd1-474d-81a1-ffb01cb4de9e
- date added to LUP
- 2025-07-14 11:33:08
- date last changed
- 2025-07-15 03:00:11
@article{8610341d-ebd1-474d-81a1-ffb01cb4de9e,
abstract = {{<p>Bladder cancer (BLCA) and diabetes mellitus (DM) are two prevalent diseases that may share molecular mechanisms, suggesting potential links between metabolic disorders and cancer. Using bioinformatics approaches, we integrated multiple databases to identify common genes between BLCA and DM, screening for potential biomarkers. CXCL12 (C-X-C motif chemokine 12, also known as stromal cell-derived factor 1, SDF-1) was ultimately identified as a key gene, followed by comprehensive analyses including immune infiltration analysis, functional enrichment analysis, survival analysis, clinicopathological correlation analysis, TIDE immune prediction scoring, and immunophenoscore (IPS) scoring comparison. The results indicate that CXCL12 is associated with altered immune cell function and tumor characteristics under elevated blood glucose levels, influencing the tumor microenvironment and promoting disease progression. The results elucidate the molecular underpinnings of BLCA and DM, establishing a basis for subsequent investigations into common mechanisms and the formulation of targeted therapeutic approaches. Research on shared biomarkers, such as CXCL12, between metabolic diseases and tumors aids in the precise prevention and control of comorbidities’ adverse effects on tumor progression. This approach significantly reduces the health burden linked to comorbidities.</p>}},
author = {{Ma, Mingyu and Wang, Shufei and Wang, Kongjia and Jiang, Bo and Li, Jingwen and Hou, Sichuan}},
issn = {{2045-2322}},
keywords = {{Biomarker; Bladder cancer; CXCL12; Diabetes mellitus; Epithelial-mesenchymal transition (EMT); Tumor microenvironment (TME)}},
language = {{eng}},
number = {{1}},
publisher = {{Nature Publishing Group}},
series = {{Scientific Reports}},
title = {{CXCL12 links bladder cancer and diabetes as a potential biomarker}},
url = {{http://dx.doi.org/10.1038/s41598-025-01357-9}},
doi = {{10.1038/s41598-025-01357-9}},
volume = {{15}},
year = {{2025}},
}